Boehringer Ingelheim and 3T Biosciences entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation cancer immunotherapies.   This second research partnership with 3T builds on the successful completion of the initial research partnership leveraging 3T’s best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform and Boehringer’s immuno-oncology efforts to boost the immune system’...